HPAPI and Low Dose Drug Products

Our manufacturing advantage

State-of-the-art containment and isolation procedures are in place throughout our development and manufacturing network, accommodating end-to-end solutions from HPAPI manufacturing to drug product. Our solid oral drug product technologies concentrate on:

• increasing fill speeds
• reducing processing time and costs
• minimizing product cross-contamination
• increasing operator safety through reducing potential exposure
• removing the risk of fire or explosion by improving the overall ease of handling
• improving product dose uniformity facilitated by highly accurate liquid fill metering

We utilize flexible high containment handling capability & facilities for a wide range of compound types and safety classifications, ranging from biologics to small molecules and can accommodate HPAPIs to OEL 0.1ng/m3.